Indian officials OK deals, quelling fears; Israel adds pricey drugs to subsidized list;

@FiercePharma: Patent cliff + R&D disappointments + regulatory issues + economic woes = a tough 2012 for pharma, Fitch says. More | Follow @FiercePharma

> Newly empowered Indian deal reviewers cleared four proposed acquisitions that had been held up, quelling fears of a chilling effect on foreign investment. News

> Israel added 77 new drugs and devices to its list of subsidized treatments, including cancer treatments such as Novartis' ($NVS) Afinitor, Bristol-Myers Squibb's ($BMY) Yervoy, and Roche's ($RHHBY) Zelboraf, and hepatitis C meds Victrelis, from Merck ($MRK), and Incivo, from Johnson & Johnson ($JNJ) and Vertex Pharmaceuticals ($VRTX). Report

> Fitch Ratings says 2012 will be a tough year for drugmakers, thanks to the patent cliff, R&D disappointments, regulatory challenges and ongoing economic woes. Report

> Merck KGaA predicts sales growth of 20% over the next three years in India, fueled equally by increases in over-the-counter and prescription treatments. Article

> The Pakistani government sealed a drug factory in Lahore, saying 27 people died after using medications produced there, possibly because of heavy-metals contamination. Story

> The Medicines Co. said it settled patent lawsuits over its anticoagulant drug Angiomax with generic challenger APP Pharmaceuticals. Report

> The European Medicines Agency warned drugmakers against the use of niche subcontractors in clinical trials, saying the fragmented assignment of tasks could strain compliance. Article

> The European Medicines Agency recommended suspending medications that contain the sedative meprobamate because of the risk of potentially deadly side effects. News

> Celgene ($CELG) elected Richard Barker, former director of the Association of the British Pharmaceutical Industry, to its board of directors. More

Biotech News

@FierceBiotech: What's making Big pay for mobile tech? Drives to streamline trials ops and, of course, sell more drugs. Story | Follow @FierceBiotech

@JohnCFierce: Scientists strip the brake off of T cells in mouse study, amp up immune response. Article | Follow @JohnCFierce

@RyanMFierce: Educators jumping aboard the Big Data bandwagon with industry clamoring for help #bioinformatics--. Article | Follow @RyanMFierce

@MarkHFierce: B.U. has found some genetic triggers behind the onset of menopause. Info could help treat age-related diseases. Release | Follow @MarkHFierce

@FierceMedDev: An interesting read: Med tech consolidation brings a need for focus. Here are 2 ways to get it. Article | Follow @FierceMedDev

> BioMarin perfects the popular rare disease drug model. News

> Columbia shares nosedive after FDA experts reject preterm birth gel. Article

Medical Devices News

> Stent advances expected to prop up European market. Story

> Covidien's Almeida to add title of chairman. Piece

> EU breast implant scandal may affect FDA's view on faster device approvals. Article

IT News

> Big Pharma testing waters with mobile tech. More

> Oracle injects genomics capability into analytics platform. News

> Medidata chief calls company 'the cloud' for clinical data. Story

> Consumers to pharma: Let's be Facebook friends (or not). Item

> Oracle, Parexel among leaders in CTMS market poised to hit $1.3B. More

> FDA brings new work flow software into its labs. Article

And Finally... Fast genome sequencing holds promise for Japanese rice farmers in need of salt-resistant plants for tsunami-flooded fields. Report

Suggested Articles

A suspected cancer-causing impurity that has been found in some blood pressure medicines has now shown up in Zantac and some OTC antacids.

Roche is steamrolling with Ocrevus, and to maintain that lead, its touting long-term data that show the earlier it’s given, the better patients do.

New data shows a significant reduction in relapse rates in patients taking Novartis' repurposed cancer drug ofatumumab.